eISSN: 2450-4459
ISSN: 2450-3517
Lekarz POZ
Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors
Editorial System
Submit your Manuscript
Search
1/2024
vol. 10
 
Share:
Send email
Share:
abstract:

Vaccinations against COVID-19 in adults in the 2023/2024 season. Recommendations of the Polish Society of Vaccinology, the Polish Society of Family Medicine, the Polish Society of Epidemiology and Physicians of Infectious Diseases and the Polish Society of Gynecologists and Obstetricians

Jacek Wysocki
1
,
Bartosz Siewert
2
,
Agnieszka Mastalerz-Migas
3
,
Aneta Nitsch-Osuch
4
,
Robert Flisiak
5
,
Magdalena Marczyńska
6
,
Piotr Sieroszewski
7
,
Agnieszka Seremak-Mrozikiewicz
8
,
Mateusz Babicki
3
,
Ilona Małecka
1

  1. Katedra i Zakład Profilaktyki Zdrowotnej, Uniwersytet Medyczny w Poznaniu
  2. Wielkopolskie Centrum Pediatrii w Poznaniu
  3. Katedra i Zakład Medycyny Rodzinnej, Uniwersytet Medyczny we Wrocławiu
  4. Zakład Medycyny Społecznej i Zdrowia Publicznego, Warszawski Uniwersytet Medyczny
  5. Klinika Chorób Zakaźnych i Hepatologii, Uniwersytet Medyczny w Białymstoku
  6. Klinika Chorób Zakaźnych Wieku Dziecięcego, Warszawski Uniwersytet Medyczny
  7. I Katedra Ginekologii i Położnictwa, Uniwersytet Medyczny w Łodzi
  8. Klinika Perinatologii, Uniwersytet Medyczny w Poznaniu
Online publish date: 2024/03/06
View full text Get citation
 
Vaccinations against COVID-19, carried out in many countries around the world since December 2020, have contributed primarily to reducing the number of cases with a severe clinical course. They have also effectively reduced the frequency of hospitalizations and the number of deaths caused by COVID-19. However, due to the changing epidemiological situation, increasing number of virus mutations, and low vaccination rates in Poland, many questions arise regarding the optimal vaccine strategy. First, diagnostics remain crucial both at the level of primary health care and at the public health level. Gathered data allows vaccine producers to effectively update the composition of available vaccines. Currently, it is unanimously recommended to use a monovalent vaccine, including the SARS-CoV-2 Omikron XBB.1.5 subvariant, in the 2023/2024 season. Thanks to cross-reactions, this composition is intended to protect not only against the XBB.1.5 variant itself but also against new variants with a similar antigenic composition. The most probable long-term solution will be to arrange COVID-19 vaccinations in a similar way to other seasonal vaccinations. That implementation should take place in accordance with the National Immunization Schedule.
keywords:

COVID-19, SARS-CoV-2, vaccination, recommendations
FEATURED PRODUCTS
BOOKS
• Choroby alergiczne w praktyce lekarza rodzinnego • Medycyna rodzinna.
Podręcznik dla lekarzy i studentów
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.